Revuforj, Syndax Pharmaceuticals
The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...
Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...
Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...
In recent trading, Syndax Pharmaceuticals Inc (SNDX) stock price has shown some volatility, fluctuating -27.42% over the last five trades and -20.41% over the past 30 trades. This represents a notable ...
The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with ...
While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
GlobalData on MSN5d
Syndax’s stock sinks by 25% despite AML trial meeting primary endpointDespite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback